Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for Residual Insomnia in MDD
NCT06843187Phase 2Terminated
- Sponsor
- Unity Health Toronto
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Insomnia comparing Lemborexant with Placebo (2 arms). Primary endpoints: Feasibility Outcomes at 13 weeks and Tolerability Outcomes at 10 weeks. Started Sep 2024; status: terminated.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06843187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843187.